Baugier de Materre

Peripheral T‐cell lymphoma (PTCL) is a heterogeneous group of clinically aggressive diseases associated with poor outcome. Despite progress in the last several years, resulting in a deeper understanding of the natural history and biology of PTCL based on molecular profiling and next‐generation sequencing, there is a need for improvement in efficacy of chemotherapeutic regimens for newly diagnosed patients.